IP Library Granted Patent US 8,492,365
Granted Patent B2
US 8,492,365 · App. 12/481,368 · Granted Jul 23, 2013

7-substituted tetracycline compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,365
App. No.
12/481,368
Granted
Jul 23, 2013
Kind
B2
Abstract

The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Claims (33)

1. A substituted tetracycline compound of Formula I:

wherein:

X is CHC(R 13 Y′Y), CR 6′ R 6 , C═CR 6′ R 6 , S, NR 6 or O;

R 2 , R 2′ , R 4′ and R 4″ are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R 4 is NR 4′ R 4″ , alkyl, alkenyl, alkynyl, hydroxyl, halogen or hydrogen;

R 3 , R 10 , R 11 and R 12 are each independently hydrogen or a pro-drug moiety;

R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy or aryl carbonyloxy;

R 6 and R 6′ are each independently hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl;

R 7 is substituted alkyl, substituted alkynyl or substituted amino,

wherein said substituted alkyl is substituted with one or more groups selected from hydroxyl, heteroaryl, substituted phenyl, carbonyl and silyl,

wherein said substituted alkynyl is substituted with one or more groups selected from hydroxyl, carbonyl, cycloalkyl and cycloalkenyl, and

wherein said substituted amino is substituted with one or two groups selected from alkenyl, alkylnyl and aryl;

R 9 is hydrogen;

R 8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl;

R 13 is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl; and

Y′ and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, amido, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl,

or pharmaceutically acceptable salts thereof.

2. The tetracycline compound of claim 1 , wherein R 4 is NR 4′ R 4″ ; X is CR 6 R 6′ ; R 2 , R 2′ , R 6 , R 6′ , R 8 , R 10 , R 11 and R 12 are each hydrogen; R 4′ and R 4″ are lower alkyl; and R 5 is hydroxyl or hydrogen.

3. The tetracycline compound of claim 2 , wherein R 4′ and R 4″ are each methyl and R 5 is hydrogen.

4. The tetracycline compound of claim 1 , wherein R 7 is alkyl substituted with heteroaryl or substituted phenyl.

5. The tetracycline compound of claim 4 , wherein R 7 is alkyl substituted with substituted phenyl.

6. The tetracycline compound of claim 5 , wherein said phenyl is substituted with one or more groups selected from alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, arylalkyl, aminoalkyl, carboxylate, alkylcarbonyl, arylcarbonyl, alkenylcarbonyl, arylalkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylthiocarbonyl, thiocarboxylate, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, amino, acylamino, alkoxycarbonylamino, amido, cyano, nitro, imino, silyl, alkylthio, arylthio, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, phosphate, phosphonato, phosphinato, sulfhydryl, azido, heterocyclyl, aryl and heteroaryl.

7. The tetracycline compound of claim 4 , wherein R 7 is alkyl substituted with heteroaryl.

8. The tetracycline compound of claim 7 , wherein said heteroaryl is substituted with one or more groups selected from alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, arylalkyl, aminoalkyl, carboxylate, alkylcarbonyl, arylcarbonyl, alkenylcarbonyl, arylalkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylthiocarbonyl, thiocarboxylate, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, amino, acylamino, alkoxycarbonylamino, amido, cyano, nitro, imino, silyl, alkylthio, arylthio, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, phosphate, phosphonato, phosphinato, sulfhydryl, azido, heterocyclyl, aryl and heteroaryl.

9. The tetracycline compound of claim 7 , wherein said heteroaryl is pyridyl.

10. The tetracycline compound of claim 1 , wherein R 7 is alkyl substituted with carbonyl, wherein said carbonyl is substituted with alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy or amino.

11. The tetracycline compound of claim 1 , wherein R 7 is alkynyl substituted with carbonyl, wherein said carbonyl is substituted with alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy or amino.

12. The tetracycline compound of claim 1 , wherein R 7 is alkynyl substituted with one or more groups selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

13. The tetracycline compound of claim 1 , wherein R 7 is amino substituted with one or two aryl.

14. The tetracycline compound of claim 13 , wherein said aryl is heteroaryl selected from pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidyl and pyrazinyl.

15. A substituted tetracycline compound selected from:

16. A pharmaceutical composition comprising a therapeutically effective amount of a tetracycline compound of claim 1 or 15 and a pharmaceutically acceptable carrier.

17. The tetracycline compound of claim 1 , wherein R 7 is substituted methyl.

Assignments (9)
TERMINATION OF LIEN ON PATENTS Recorded Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →
NOTICE Recorded Mar 8, 2013
From: PARATEK PHARMACEUTICALS, INC.
To: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
Reel/Frame 029940/0106 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2009
From: MIDCAP FINANCIAL, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 023348/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2009
From: RENNIE, GLEN; KOZA, DARRELL
To: TRUSTEES OF TUFTS COLLEGE
Reel/Frame 023139/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2009
From: NELSON, MARK L.; ISMAIL, MOHAMED Y.
To: TRUSTEES OF TUFTS COLLEGE; PARATEK PHARMACEUTICALS, INC.
Reel/Frame 023139/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2009
From: MCINTYRE, LAURA; BOWSER, TODD E.; BHATIA, BEENA; MESSERSMITH, DAVID; SHEAHAN, PAUL; HAWKINS, PAUL; VERMA, ATUL; WARCHOL, TADEUSZ; BANDARAGE, UPUL; FRECHETTE, ROGER; VISKI, PETER
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 023139/0726 →
SECURITY AGREEMENT Recorded Jul 6, 2009
From: PARATEK PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL, LLC
Reel/Frame 022917/0112 →